Protalix BioTherapeutics (PLX) Stock: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.64
-0.09 (-3.30%)
▼
5d:
+0.76%
30d:
+0.76%
90d:
+28.78%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.64, which is considered extended relative to its 30-day fair value range of $2.34 to $2.58. From a valuation perspective, the stock is trading at a premium (Forward PE: 52.8) compared to its historical average (32.6). At these levels, the market is pricing in 17.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.75. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: PLX scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+316.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.75. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: PLX scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+316.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.34 -
$2.58
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 316.7% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 17.4% growth expectation is conservative given 2241% recent growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.34 -
$2.58
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.53
Resistance Level
$2.75
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
52.80
Wall Street Target
$11.00
(+316.7%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+17.4% premium
PE vs Historical
52.8 vs 32.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.4%
(market-implied from PE analysis)
1-Year Target
$3.10
(+17%)
2-Year Target
$3.64
(+38%)
3-Year Target
$4.27
(+62%)
3-Yr Target (if PE normalizes)
(PE: 53→33)
PE COMPRESSION
$2.64
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 52.8, Growth: -79.2%)
$1.92
(+-27%)
Base:
(SPY PE: 20.2, Growth: -79.2%)
$0.74
(-72%)
Bear:
(PE: 17.1, Growth: -79.2%)
$0.62
(-76%)
📈
Valuation based on Current Earnings
Trailing PE: 11.38 | Current EPS (TTM): $0.24
Bull Case
$1.50
(-43%)
Analyst growth -50.0%, PE expands to 12.5
Base Case
$1.36
(-48%)
Market implied -50.0%, PE stable at 11.4
Bear Case
$1.86
(-30%)
Severe decline -20.0%, PE contracts to 9.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 11:50 AM ET
Data refreshes hourly during market hours. Next update: 12:50 PM
Data refreshes hourly during market hours. Next update: 12:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
